Biosergen AB

BIOSGN.ST

Biotechnology · Healthcare

Price

kr 2.08

-0.10 (-4.59%)

Market Cap

kr 4.9M

Exchange

Stockholm Stock Exchange

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+339.0% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 535K (2021) → 2.3M (2025)

Winston Score History

The full picture

Biosergen AB is a small Swedish biotechnology company focused on developing new antifungal medicines. Its main drug candidate, BSG005, is designed to treat serious fungal infections that are difficult to cure with existing treatments — particularly in patients with weakened immune systems, such as those undergoing cancer therapy or organ transplants. The company does not yet sell any commercial products.

Biosergen earns no revenue today and funds its research through equity raises and grants, which is typical for early-stage drug developers. It operates primarily out of Sweden and is a very small company with a market value near zero, meaning it carries significant financial risk. The key question for Biosergen is whether BSG005 can successfully pass clinical trials and attract a larger pharmaceutical partner — failure in trials or an inability to raise more funding would likely threaten the company's survival.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

-131.9% YoY

YoY Growth Rate

Earnings declining

R&D Spend

kr 0/ year

Research and development spending

Insider Activity

42.3%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~5 months

kr 15M cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

Biosergen AB has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-351.9%

Weak — -351.9% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

4/8 quarters

Earnings inconsistent quarter-to-quarter

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial